PaxMedica, Inc. Common Stock (PXMD)
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Sector: Biotechnology
Industry: Biotechnology
PaxMedica, Inc. Common Stock
- 1:17Reverse splitOct 31, 202317 shares → 1
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $3.92M | $1.79M | $2.23M | $937K | $484K |
| Selling, General, and Administrative | $12.23M | $8.82M | $4.97M | $4.63M | $114K |
| Other | $0 | $0 | $0 | $224 | $0 |
| Total Operating Expenses | $16.14M | $10.6M | $7.2M | $5.57M | $599K |
| Operating Income (EBIT) | -$16.14M | -$10.6M | -$7.2M | -$5.57M | -$599K |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $9K | $5K | $2.81M | $609K | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$2.14M | -$4.2M | -$3.03M | -$2.26M | $0 |
| Income Before Tax (EBT) | -$18.29M | -$14.8M | -$10.23M | -$7.83M | -$599K |
| Income Tax Expense | $0 | $4.19M | $2.81M | $663K | $0 |
| Net Income | -$18.29M | -$14.8M | -$13.04M | -$8.49M | -$599K |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -11.00 | -28.73 | -18.81 | -13.42 | -0.06 |
| Diluted EPS | -11.00 | -28.73 | -18.81 | -13.42 | -0.06 |
| Weighted Average OS | 1.66M | 514,216 | 692,910 | 589,198 | 589,198 |
| EBITDA | -$16.14M | -$16.51M | -$7.2M | -$5.62M | -$599K |
| EBITDA Margin | - | - | - | - | - |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $4.71M | $1.9M | $444K | $1.12M | $25K | $9K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $4.71M | $1.9M | $444K | $1.12M | $25K | $9K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $970K | $302K | $0 | $0 | $0 | $0 |
| Total Current Assets | $5.68M | $2.2M | $444K | $1.12M | $25K | $9K |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $205K | $0 | $0 | $0 |
| Total Long-Term Assets | $0 | $0 | $205K | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $5.68M | $2.2M | $649K | $1.12M | $25K | $9K |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $812K | $722K | $736K | $346K | $41K | $0 |
| Short-Term Debt | $0 | $174K | $0 | $612K | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $634K | $0 | $0 |
| Other Current Liabilities | $788K | $661K | $9.34M | $3.42M | $0 | $0 |
| Total Current Liabilities | $1.8M | $2.1M | $10.76M | $5.75M | $123K | $7K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $500K | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $500K | $915K | $737K | $1.06M | $0 | $2K |
| Other Liabilities | $0 | -$915K | -$737K | -$1.06M | $0 | -$2K |
| Total Liabilities | $2.3M | $2.1M | $10.76M | $5.75M | $123K | $7K |
| Stockholders' Equity | ||||||
| Preferred Stock | $5 | $5 | $270 | $270 | $766K | $232K |
| Common Stock | $740 | $71 | $691 | $578 | $0 | $0 |
| Retained Earnings | -$52.03M | -$33.74M | -$18.94M | -$8.71M | -$864K | -$229K |
| Comprehensive Income & Other | -$740 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $55.41M | $33.85M | $8.83M | $4.08M | $766K | $232K |
| Total Equity | $3.39M | $109K | -$10.11M | -$4.63M | -$98K | $3K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $5.68M | $2.2M | $649K | $1.12M | $25K | $9K |
| Supplementary Data | ||||||
| Total Debt | $0 | $174K | $0 | $612K | $0 | $0 |
| Net Debt | -$4.71M | -$1.73M | -$444K | -$512K | -$25K | -$9K |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||
| Net Income | -$18.29M | -$14.8M | -$10.23M | -$7.83M | -$599K |
| Depreciation & Amortization | $0 | $0 | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $5.2M | $4.42M | $1.34M | $2.26M | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $456K | $114K | $250K | $393K | $54K |
| Other Working Capital | -$122K | -$64K | $102K | $569K | $63K |
| Total Working Capital Change | $334K | $50K | $352K | $962K | $117K |
| Other Non-Cash Items | $1.98M | $4.26M | $3.03M | $2.25M | $63K |
| Net Cash from Operating | -$10.77M | -$6.07M | -$5.51M | -$2.35M | -$419K |
| Investing Activities | |||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | |||||
| Debt Repaid | - | - | - | -$2.93M | - |
| Common Stock Issuance | $11.95M | $6.02M | $5M | $0 | $0 |
| Common Stock Repurchases | -$196K | -$35K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$626K | -$35K | -$167K | $520K | $435K |
| Net Cash from Financing | $13.58M | $7.53M | $4.83M | $3.45M | $435K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $2.81M | $1.46M | -$680K | $1.1M | $16K |
| Supplementary Data | |||||
| Operating Cash Flow | -$10.77M | -$6.07M | -$5.51M | -$2.35M | -$419K |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$10.77M | -$6.07M | -$5.51M | -$2.35M | -$419K |
| Cash at Beginning | $1.9M | $444K | $1.12M | $25K | $9K |
| Cash at End | $4.71M | $1.9M | $444K | $1.12M | $25K |